CTIS2022-502040-13-00Active, not recruitingPhase 1
Magrolimab plus intensive chemotherapy in newly diagnosed ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC) - MAGROLIC
niversity of Leipzig0 sites108 target enrollmentStarted: March 29, 2023Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 108
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •AML or MDS-IB-2 according to WHO 2022 criteria, Intermediate or adverse risk” ELN 2022 category (for both MDS or AML), Intention to undergo intensive chemotherapy (CPX-351 or 7+3”) followed by allogeneic HSCT
Exclusion Criteria
- •Not eligible for intensive chemotherapy, Any prior treatment for AML or high-risk MDS (including magrolimab) except hydoxyurea, Harboring a FLT3mut, regardless of FLT3-ITD or FLT3-TKD mutation status, Acute promyelocytic leukemia (APL), Inadequate cardiac, pulmonary, renal, hepatic function, ECOG =3, Active and uncontrolled infection, Diagnosed or treated for another malignancy within 1 year before registration
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Treatment With Chemotherapy and Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)Diffuse Large B Cell Lymphoma and HIV InfectionEUCTR2006-003750-23-ESFundación PETHEMA
Active, not recruiting
Phase 1
An investigational immunotherapy study of Nivolumab combined with chemoradiotherapy , compared to chemoradiotherapy by itself, in patients with bladder cancer, not undergoing cystectomymuscle-invasive bladder cancer (MIBC)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003447-34-GRHellenic Genitourinary Cancer Group (HGUCG)78
Recruiting
Phase 2
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.2024-515064-31-00Medical University Of Gdansk84
Completed
Phase 2
Phase II study of combination chemotherapy and high-dose chemotherapy in treating young children with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumorsmedulloblastoma or supratentorial primitive neuroectodermal tumorsJPRN-UMIN000000546Japanese Pediatric Brain Tumor Consortium40
Recruiting
Phase 2
A phase 2 study of chemotherapy and durvalumab with TRT in patients with ED-SCLCextensive disease small cell lung cancer(ED-SCLC)JPRN-jRCTs071200101Takayama Koichi60